POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Clinical trials for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new POORLY DIFFERENTIATED THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shrinks thyroid tumors before surgery in early trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib given before surgery in 30 people with thyroid cancer that has a specific genetic change (RET alteration). The goal is to see if the drug can shrink tumors and make surgery more successful. Participants take selpercatinib for a shor…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 08:04 UTC
-
New drug cocktail shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis study tests a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with a type of thyroid cancer that no longer responds to radioactive iodine and has worsened after one prior targeted therapy. The goal is to see if this mix can shrink or control th…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis study tested whether the drug trametinib can help radioactive iodine (RAI) work better in people with advanced thyroid cancer that has spread or come back. It included 34 adults whose cancer had a specific gene change (RAS mutation) or no changes in RAS or RAF genes. The goa…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New combo therapy targets deadly thyroid cancer
Disease control OngoingThis study tests whether two drugs, lenvatinib and pembrolizumab, work together to control advanced anaplastic thyroid cancer that cannot be removed by surgery or has spread. About 25 adults with stage IVB or IVC disease will receive the combination. The goal is to see if it impr…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Your own tumor cells could fight your cancer: new trial tests personalized T-Cell therapy
Disease control OngoingThis phase 2 trial tests a personalized cell therapy called LN-145 for people with certain advanced cancers (like ovarian, breast, thyroid, or bone cancers) that have not responded to treatment or have returned. The therapy uses a patient's own immune cells, taken from their tumo…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Promising combo therapy targets deadly thyroid cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with aggressive thyroid cancers (anaplastic or poorly differentiated) live longer. About 50 adults with advanced or inoperable cancer will receive different drug combinati…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New drug combo shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis study tests whether a drug called PDR001, combined with either trametinib or dabrafenib, is safe and effective for people with thyroid cancer that no longer responds to standard radioactive iodine treatment. The trial enrolled 19 adults whose cancer had worsened. The main go…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:01 UTC